The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Are they supplied by this company>?
https://www.bindingsite.com/en?disclaimer=1
Does anyone know who’s test this is?
NCYT buy GDR - rationale? NCYT must be looking to use their MC/cash to diversify for more sustainable revenues I would think so attraction of GDR could be Hearing Test potential revenues maybe but Covid? Maybe US presence for Covid with BC relationship - do they have any US presence? But product overlap makes it look unlikely to me and if I was NCYT I’d want existing or very near revenue streams.
GDR & SNG both spiked up c.8%
I’d guess they are just employees who want to to exercise/sell some of their options now the price is nicely up. Nothing wrong with that of course. Smart employees will often sell some of their options as they vest when the price has risen and bank some profit and keep the rest for future vesting and ideally more rises. So generally I don’t think this is indicative of anything wrt future RNSs, and SP rises/falls.
Better still, were the company to be acquired by a larger company with the right distribution channels this is a global market of billions. Not necessarily B2C but for hospitals for example. My wife was in hospital recently (not Covid) and all the nurses and visitors were required to wear the destroy their PPE every time they went near her in case she got an infection from them as her immune system was down. The market it is therefore billions and if it works as it says on the tin, it can change usage patterns, efficacy and costs as it protects a lot longer.
Was about to say this as well. Think what RachelsDad may have meant was he is not on the Executive Mgmt team who run the company day-to-day but he is most certainly a Director and Chair of the BoD.
Me too - some new customers/contracts I suspect...
Hi All, can anyone share any business details about DIVOC? I’m thinking revenue, profitability, # of employees, existing customers, facilities etc. Tia
Just to say ii held up Monday (Lev 2 was understandably patchy) but as usual very hard for retail investors to sell in the light of the situation/volumes. I managed to offload some testing Pharma (not NCYT) but only by dropping the sells to small amounts (2-3000) and perseverance. We all know it and be naive to not realise that scale counts but RI’s really are at a big disadvantage in busy times and this isn’t fair in what should be an ‘open market’.
+18% - what’s the story
Refresh your screen
No I wouldn’t tbh as I’m no youngster! Guess Q1 2021 will getting distribution, priorities, schedules etc for the 59% (?) who want it. IMO - yours?
Technick, totally agree re derogatory comments and all the 'personal chatter', be much better if we kept content to useful information so we can all make decisions on what we do next.
All, as time marches on, I am sure we are all getting a little nervous that GDR are potentially running out of time to meaningfully get to market and at scale and Technick’s point re channel sales is very pertinent here I think. I am sure many of us know from personal experience that selling via channels or distributors (B2B) can be much harder, slower, and frustrating than direct as you are not selling to the end customer (not an individual as in B2C but Govts and P.Sector authorities). Pls correct me if I’m wrong but we have DIVOC in India and BC in US and other distributors in S.Africa. I am wondering therefore if GDR’s ability to push sales as (everyone understandably keeps questioning) is hampered by the fact that we are working through Partners. Of course it makes sense that they did this as GDR do not have the coverage in their stated target markets (India, US and S.Africa) to sell direct but might the problem be that these channels are not as able as GDR staff to explain the benefits of our products vs the competition that would drive sales? Maybe this is being unfair on these channels but the comments I’ve seen re some of these channel staff implies they probably need more GDR support to sell why GDR is a great solution.
Secondly, as we still await many approvals in order to sell, does this same factor of working with a channel hamper those efforts as surely the channels will be lobbying to get this done for them and us.
And finally, wrt the window of opportunity closing, when do we see this being based on today’s info wrt vaccines etc? I am aware from my contacts that the UK Consortium vaccine is likely to be given to NHS and front-line staff in late Dec and there will obviously be a period where testing continues but not sure of the situation in our target markets. Be great to get everyone’s thoughts on this and the other points.
Agree, great tech and getting more good people onboard now - also a good Covid stock IMO. I've held/traded it twice now, with good returns of 20+%. Historically it trades up to 22p and down again in about a 5p range but strangely never seems to break out of that so sold near top each time. Will buy again. Be interesting to see what’s driving this up-tick.
I believe the Tik-Tok decision been parked by Trump till after the election and if he wins, Biden pay take a more conciliatory view on relationships with China so I wouldn’t hold your breath on that one.
Think this is a naive and unfair commentary. CEO has done an excellent job of turning this around and setting it on a +ve strategic path. It’s not possible or realistic to expect weekly RNSs & hype to keep boosting the share price - rather a sure move in the right direction is good news and creates a good strategic direction for the business to flourish and grow over time. Right now, 160p is a reasonable valuation based on the numbers and as more is delivered over time this will grow. If you want a quick killing I’d suggest a look at some high risk pharma stocks and look in here in 4-6mths time. I am an ex CEO so do know a little bit about this.
Yep, Technik is right
Well spotted?